A Phase III randomized controlled trial involving 492 patients with advanced pancreatic cancer has revealed striking survival improvements with the investigational drug daraxonrasib. The data, published in The New England Journal of Medicine, shows median overall survival increased from 5.7 months with standard chemotherapy to 11.2 months with the new targeted therapy—a 96% improvement in survival duration. This represents a 60% reduction in death risk among patients receiving daraxonrasib, significantly outperforming conventional treatment approaches. The multi-national study, conducted across the United States, European Union, and Canada, enrolled adult patients with advanced pancreatic cancer and confirmed KRAS mutations. These results represent a watershed moment in pancreatic cancer treatment, where a previously intractable molecular target has finally yielded to therapeutic innovation.
Was this article helpful?
